A Becker1. 1. Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada.
Abstract
OBJECTIVE: The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY: Available published literature, including published abstracts, is reviewed. RESULTS: In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a significant decrease in exercise-induced bronchoconstriction 20 to 24 hours postdose after 2 days of treatment. For children with chronic asthma, only one study of the regular use of a leukotriene receptor antagonist has been published. The efficacy and safety of montelukast in children aged 6 to 14 years with asthma (n = 336) were studied during an 8-week, double-blind, placebocontrolled trial. There was a significantly greater improvement in forced expiratory volume in 1 second (FEV1) from baseline for the montelukast group (8.23%) compared with the placebo group (3.58%). There was a significant decrease in the use of a 3-agonist for symptom relief, as well as in the percentage of days and percentage of patients with asthma exacerbations. An asthma specific quality-of-life (QOL) questionnaire revealed a significant overall improvement in QOL and a significant improvement in the QOL domains for symptoms, activity and emotions in montelukast recipients. There was no significant difference between montelukast and placebo recipients in the frequency of adverse events, with the exception of allergic rhinitis, which was more prevalent in the placebo group. An open label follow-up of patients from the above study was undertaken. The effect of montelukast on FEV1 was consistent for up to 1.4 years, with the increase in FEV1 being not significantly different from that in a small control group treated with inhaled beclomethasone dipropionate. QOL remained significantly improved during the open treatment period. CONCLUSIONS:Montelukast appears effective and safe for the treatment of children with asthma.
RCT Entities:
OBJECTIVE: The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY: Available published literature, including published abstracts, is reviewed. RESULTS: In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a significant decrease in exercise-induced bronchoconstriction 20 to 24 hours postdose after 2 days of treatment. For children with chronic asthma, only one study of the regular use of a leukotriene receptor antagonist has been published. The efficacy and safety of montelukast in children aged 6 to 14 years with asthma (n = 336) were studied during an 8-week, double-blind, placebocontrolled trial. There was a significantly greater improvement in forced expiratory volume in 1 second (FEV1) from baseline for the montelukast group (8.23%) compared with the placebo group (3.58%). There was a significant decrease in the use of a 3-agonist for symptom relief, as well as in the percentage of days and percentage of patients with asthma exacerbations. An asthma specific quality-of-life (QOL) questionnaire revealed a significant overall improvement in QOL and a significant improvement in the QOL domains for symptoms, activity and emotions in montelukast recipients. There was no significant difference between montelukast and placebo recipients in the frequency of adverse events, with the exception of allergic rhinitis, which was more prevalent in the placebo group. An open label follow-up of patients from the above study was undertaken. The effect of montelukast on FEV1 was consistent for up to 1.4 years, with the increase in FEV1 being not significantly different from that in a small control group treated with inhaled beclomethasone dipropionate. QOL remained significantly improved during the open treatment period. CONCLUSIONS:Montelukast appears effective and safe for the treatment of children with asthma.
Authors: M Griffin; J W Weiss; A G Leitch; E R McFadden; E J Corey; K F Austen; J M Drazen Journal: N Engl J Med Date: 1983-02-24 Impact factor: 91.245
Authors: B Dahlén; M Kumlin; D J Margolskee; C Larsson; H Blomqvist; V C Williams; O Zetterström; S E Dahlén Journal: Eur Respir J Date: 1993-07 Impact factor: 16.671
Authors: Y Kikawa; T Miyanomae; Y Inoue; M Saito; A Nakai; Y Shigematsu; S Hosoi; M Sudo Journal: J Allergy Clin Immunol Date: 1992-06 Impact factor: 10.793